This document was developed by the Centre of Excellence in Severe Asthma. It provides an overview of benralizumab treatment, eligibility criteria, enrolment, precautions/adverse effects and procedures for administration. This document has been developed as a guide only. Any local recommendations and requirements must be considered when implementing these recommendations into practice.
Download the document by clicking on the image below:
You can learn more about Monoclonal Antibodies as add-on therapies for severe asthma at the Severe Asthma Toolkit.